These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 33482697)
41. Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma? Seystahl K; Weller M Expert Opin Investig Drugs; 2012 May; 21(5):605-17. PubMed ID: 22413865 [TBL] [Abstract][Full Text] [Related]
42. Efficient inhibition of in vivo human malignant glioma growth and angiogenesis by interferon-beta treatment at early stage of tumor development. Hong YK; Chung DS; Joe YA; Yang YJ; Kim KM; Park YS; Yung WK; Kang JK Clin Cancer Res; 2000 Aug; 6(8):3354-60. PubMed ID: 10955823 [TBL] [Abstract][Full Text] [Related]
47. Inhibition of CYP4A by a novel flavonoid FLA-16 prolongs survival and normalizes tumor vasculature in glioma. Wang C; Li Y; Chen H; Zhang J; Zhang J; Qin T; Duan C; Chen X; Liu Y; Zhou X; Yang J Cancer Lett; 2017 Aug; 402():131-141. PubMed ID: 28602979 [TBL] [Abstract][Full Text] [Related]
48. The glioblastoma vasculature as a target for cancer therapy. Dimberg A Biochem Soc Trans; 2014 Dec; 42(6):1647-52. PubMed ID: 25399584 [TBL] [Abstract][Full Text] [Related]
49. Recent advance in molecular angiogenesis in glioblastoma: the challenge and hope for anti-angiogenic therapy. Zhang M; Ye G; Li J; Wang Y Brain Tumor Pathol; 2015 Oct; 32(4):229-36. PubMed ID: 26437643 [TBL] [Abstract][Full Text] [Related]
50. Vessel co-option and resistance to anti-angiogenic therapy. Kuczynski EA; Reynolds AR Angiogenesis; 2020 Feb; 23(1):55-74. PubMed ID: 31865479 [TBL] [Abstract][Full Text] [Related]
51. Glioblastoma: a pathogenic crosstalk between tumor cells and pericytes. Caspani EM; Crossley PH; Redondo-Garcia C; Martinez S PLoS One; 2014; 9(7):e101402. PubMed ID: 25032689 [TBL] [Abstract][Full Text] [Related]
52. Mefloquine as a dual inhibitor of glioblastoma angiogenesis and glioblastoma via disrupting lysosomal function. Wan B; Wu Z; Zhang X; Huang B Biochem Biophys Res Commun; 2021 Nov; 580():7-13. PubMed ID: 34607260 [TBL] [Abstract][Full Text] [Related]
53. Aspirin Affects Tumor Angiogenesis and Sensitizes Human Glioblastoma Endothelial Cells to Temozolomide, Bevacizumab, and Sunitinib, Impairing Vascular Endothelial Growth Factor-Related Signaling. Navone SE; Guarnaccia L; Cordiglieri C; Crisà FM; Caroli M; Locatelli M; Schisano L; Rampini P; Miozzo M; La Verde N; Riboni L; Campanella R; Marfia G World Neurosurg; 2018 Dec; 120():e380-e391. PubMed ID: 30144594 [TBL] [Abstract][Full Text] [Related]
54. Cediranib: profile of a novel anti-angiogenic agent in patients with glioblastoma. Dietrich J; Wang D; Batchelor TT Expert Opin Investig Drugs; 2009 Oct; 18(10):1549-57. PubMed ID: 19671039 [TBL] [Abstract][Full Text] [Related]
55. New molecular targets in angiogenic vessels of glioblastoma tumours. Anderson JC; McFarland BC; Gladson CL Expert Rev Mol Med; 2008 Aug; 10():e23. PubMed ID: 18684337 [TBL] [Abstract][Full Text] [Related]
57. Anti-Angiogenics: Their Value in Colorectal Cancer Therapy. Seeber A; Gunsilius E; Gastl G; Pircher A Oncol Res Treat; 2018; 41(4):188-193. PubMed ID: 29562227 [TBL] [Abstract][Full Text] [Related]
58. Mechanisms of evasion to antiangiogenic therapy in glioblastoma. Rose SD; Aghi MK Clin Neurosurg; 2010; 57():123-8. PubMed ID: 21280504 [No Abstract] [Full Text] [Related]
59. Anti-angiogenic therapies in the management of glioblastoma. Schulte JD; Aghi MK; Taylor JW Chin Clin Oncol; 2021 Aug; 10(4):37. PubMed ID: 32389001 [TBL] [Abstract][Full Text] [Related]